These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3441445)

  • 1. L364718, a new CCK antagonist, inhibits biological actions of CCK in conscious dogs.
    Hosotani R; Chowdhury P; McKay D; Rayford PL
    Peptides; 1987; 8(6):1061-4. PubMed ID: 3441445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of L364718, a new CCK antagonist, on amylase secretion in isolated rat pancreatic acini.
    Hosotani R; Chowdhury P; McKay D; Rayford PL
    Pancreas; 1988; 3(1):95-8. PubMed ID: 2452436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-364,718, a new CCK antagonist, inhibits postprandial pancreatic secretion and PP release in dogs.
    Hosotani R; Chowdhury P; Rayford PL
    Dig Dis Sci; 1989 Mar; 34(3):462-7. PubMed ID: 2646088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of non-peptidal CCK receptor antagonist (L-364,718) on pancreatic responses to cholecystokinin, gastrin, bombesin, and meat feeding in dogs.
    Konturek SJ; Tasler J; Konturek JW; Cieszkowski M; Szewczyk K; Hładij M; Anderson PS
    Gut; 1989 Jan; 30(1):110-7. PubMed ID: 2920915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of two cholecystokinin-receptor antagonists, loxiglumide and L-364,718, on the pancreatic secretory response to intraduodenal tryptophan in dogs.
    Niebergall-Roth E; Teyssen S; Wetzel D; Hartel M; Beglinger C; Riepl RL; Singer MV
    Scand J Gastroenterol; 1996 Jul; 31(7):723-32. PubMed ID: 8819225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of L-364,718 on GRP-stimulated pancreatic and gastric secretions and GI peptides in conscious dogs.
    Hosotani R; Chowdhury P; Huang YS; McKay D; Yajima H; Rayford PL
    Pancreas; 1989; 4(5):550-5. PubMed ID: 2813326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of synthetic human cholecystokinin-33 on pancreatic blood flow in dogs.
    Doi R; Hosotani R; Inoue K; Kogire M; Sumi S; Fujii N; Yajima H; Rayford PL; Tobe T
    Pancreas; 1990 Sep; 5(5):615-20. PubMed ID: 2235971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of endogenous cholecystokinin on vagally stimulated pancreatic secretion in dogs.
    Kim CK; Lee KY; Wang T; Sun G; Chang TM; Chey WY
    Am J Physiol; 1989 Dec; 257(6 Pt 1):G944-9. PubMed ID: 2481981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of L-364,718 on pancreatic exocrine and endocrine secretion in the rat.
    Nakamura T; Fujii M; Okabayashi Y; Tani S; Fujisawa T; Koide M; Otsuki M
    Pancreas; 1990 Mar; 5(2):216-21. PubMed ID: 1690422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous CCK is not involved in the regulation of interdigestive gastrointestinal and gallbladder motility in conscious dogs.
    Mizumoto A; Ueki S; Ohtawa M; Itoh Z
    Regul Pept; 1992 Oct; 41(3):249-56. PubMed ID: 1438992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of L364718 on interdigestive pancreatic exocrine secretion and gastroduodenal motility in conscious sheep.
    Onaga T; Mineo H; Kato S
    Regul Pept; 1997 Jan; 68(2):139-46. PubMed ID: 9110386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrapancreatic cholinergic nerves mediate cholecystokinin-stimulated pancreatic polypeptide release.
    Kuvshinoff BW; Brodish RJ; Fink AS; McFadden DW
    J Surg Res; 1994 May; 56(5):397-401. PubMed ID: 8170138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a new diphenylpyrazolidinone cholecystokinin antagonist in vitro isolated rat pancreatic acini.
    Akiyama T; Tachibana I; Otsuki M
    Int J Pancreatol; 1993 Oct; 14(2):167-73. PubMed ID: 7506744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exocrine effects of the CCK antagonist L-364,718 in canine pancreatic autografts.
    Garvin PJ; Niehoff ML; Burton FR; Dysarz FA; Meadow R; Solomon H
    J Surg Res; 1996 Feb; 61(1):256-9. PubMed ID: 8769975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic CCK8 analogs with antagonist activity on pancreatic receptors: in vivo study in the rat, compared to non-peptidic antagonists.
    Nagain C; Galas MC; Lignon MF; Rodriguez M; Martinez J; Rozé C
    Pancreas; 1991 May; 6(3):275-81. PubMed ID: 1713671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural mechanisms of pancreatic polypeptide release in conscious dogs.
    Hosotani R; Chowdhury P; Huang YS; Rayford PL
    Am J Physiol; 1989 Jul; 257(1 Pt 1):G134-7. PubMed ID: 2568754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cholecystokinin in pancreatic bicarbonate secretion in dogs.
    Jo YH; Lee KY; Chang TM; Chey WY
    Pancreas; 1991 Mar; 6(2):197-201. PubMed ID: 1886888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CCK antagonist L 364718 on meal-induced pancreatic secretion in rats.
    O'Rourke MF; Reidelberger RD; Solomon TE
    Am J Physiol; 1990 Feb; 258(2 Pt 1):G179-84. PubMed ID: 1689547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.
    Lotti VJ; Pendleton RG; Gould RJ; Hanson HM; Chang RS; Clineschmidt BV
    J Pharmacol Exp Ther; 1987 Apr; 241(1):103-9. PubMed ID: 2437282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprandial peptide YY release is mediated by cholecystokinin.
    McFadden DW; Rudnicki M; Kuvshinoff B; Fischer JE
    Surg Gynecol Obstet; 1992 Aug; 175(2):145-50. PubMed ID: 1636140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.